Clovis Oncology Inc (CLVS)

36.03
NASDAQ : Health Care
Prev Close 35.56
Day Low/High 35.34 / 36.88
52 Wk Low/High 11.57 / 40.29
Avg Volume 3.14M
Exchange NASDAQ
Shares Outstanding 38.59M
Market Cap 1.37B
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of July 2017 Options Trading For Clovis Oncology (CLVS)

First Week of July 2017 Options Trading For Clovis Oncology (CLVS)

Investors in Clovis Oncology Inc saw new options become available this week, for the July 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit

Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Clovis Oncology, Inc.

CLVS Crosses Above Average Analyst Target

CLVS Crosses Above Average Analyst Target

In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $33.14, changing hands for $33.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Clovis Oncology Announces Q3 2016 Operating Results And Corporate Update

Clovis Oncology Announces Q3 2016 Operating Results And Corporate Update

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...

'Mad Money' Lightning Round: No Sunshine for Solar Plays

'Mad Money' Lightning Round: No Sunshine for Solar Plays

But, Jim Cramer says, he thinks Elon Musk's solar shingles look really nice.

Jim Cramer's 'Mad Money' Recap: Earnings, Politics and Uncertainty Stir the Pot

Jim Cramer's 'Mad Money' Recap: Earnings, Politics and Uncertainty Stir the Pot

Investors need to sift through the confusing crosswinds hitting the market, Jim Cramer says.

Clovis Oncology To Present At The 2016 Credit Suisse Healthcare Conference

Clovis Oncology To Present At The 2016 Credit Suisse Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick Mahaffy, the Company's President and CEO, will present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8, at 1:00pm MST.

Clovis Oncology To Announce Third Quarter 2016 Financial Results And Host Webcast Conference Call On November 3

Clovis Oncology To Announce Third Quarter 2016 Financial Results And Host Webcast Conference Call On November 3

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.

After FDA Approval, Merck Posts Better-Than-Expected Earnings

After FDA Approval, Merck Posts Better-Than-Expected Earnings

A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.

'Mad Money' Lightning Round: People Keep Underrating Cable Stocks

'Mad Money' Lightning Round: People Keep Underrating Cable Stocks

Jim Cramer says he doesn't like solar companies, but ICE is cool. Cable stocks, he says, are underrated.

Jim Cramer's 'Mad Money' Recap: These Companies Have Changed How We Live

Jim Cramer's 'Mad Money' Recap: These Companies Have Changed How We Live

Staying home is the new going out, and these companies are profiting, Cramer says.

How to Anticipate When a Positive Stock Trend Is About to Reverse

How to Anticipate When a Positive Stock Trend Is About to Reverse

Many traders follow trends, but these can change quickly, sending a stock plummeting. There are signals that will help a trader know how to avoid this type of pattern.

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.

Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish

Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish

Clovis Oncology (CLVS) gave an update on a clinical trial for its rucaparib drug on Friday, showing its candidate might be inferior to competitors.

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.

Clovis Oncology Presents Efficacy And Safety Data From New Drug Application (NDA) Population For Rucaparib In The Treatment Of Advanced Mutant BRCA Ovarian Cancer At 2016 ESMO Congress

Clovis Oncology Presents Efficacy And Safety Data From New Drug Application (NDA) Population For Rucaparib In The Treatment Of Advanced Mutant BRCA Ovarian Cancer At 2016 ESMO Congress

Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.

Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates

Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates

A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.

Jim Cramer's 'Mad Money' Recap: Blame the Banks for Today's Market Drop

Jim Cramer's 'Mad Money' Recap: Blame the Banks for Today's Market Drop

Deutsche Bank's problems have investors worried about another Lehman failure, Cramer says.

Clovis Oncology Announces Rucaparib Data Presentations At ESMO 2016 Congress

Clovis Oncology Announces Rucaparib Data Presentations At ESMO 2016 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from its rucaparib program in ovarian cancer will be presented at the annual European Society for Medical Oncology (ESMO) 2016 Congress.

Takeover Chatter Around Clovis May Be Overdone

Takeover Chatter Around Clovis May Be Overdone

Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.

'Mad Money' Lightning Round: Broadcom Is Going to $200

'Mad Money' Lightning Round: Broadcom Is Going to $200

Cramer is sticking with Weyerhaeuser and thinks Taser is a buy.

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.

Here's Why Shares of Clovis Oncology Are Higher Wednesday

Here's Why Shares of Clovis Oncology Are Higher Wednesday

Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.

Clovis Oncology Charts Suggest Aggressive Buying

Clovis Oncology Charts Suggest Aggressive Buying

The technical signs indicate the stock's price and volume are going up without a dip.

Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades

Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades

Clovis Oncology's (CLVS) stock rating was lifted to 'outperform' at Credit Suisse on takeover talk.

Morning Movers: MYL, XOM, MSFT, GIS, CLVS

Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.

Analysts' Actions -- Clovis, Altria, Sketchers, Wells Fargo and More

Analysts' Actions -- Clovis, Altria, Sketchers, Wells Fargo and More

Here are Wednesday's top research calls, including an upgrade for Clovis Oncology, downgrades for Sketchers USA and Wells Fargo and new coverage for Altria.